Kymera Therapeutics, Inc. On June 18, 2024, Joanna Horobin, M.B., Ch.B. a member of the Board of Directors (the ?Board?) of Kymera Therapeutics, Inc. (the ?Company?) and the Audit Committee of the Board (the ?Audit Committee?) and Nominating and Corporate Governance Committee of the Board (the ?Nominating and Corporate Governance Committee?), notified the Company of her resignation from the Board and all committees thereof, effective immediately. Dr. Horobin?s resignation was not the result of any disagreement with the Company on any matter relating to the Company?s operations, policies or practices. The Company thanks Dr. Horobin for her years of service as a director.

On June 18, 2024, in connection with Dr. Horobin?s resignation, and upon recommendation by the Nominating and Corporate Governance Committee, the Board appointed Jeffrey Albers, J.D., MBA, to the Audit Committee. The Audit Committee now consists of Elena Ridloff, CFA, Pamela Esposito, Ph.D. and Jeffrey Albers, J.D., MBA. The Nominating and Corporate Governance Committee now consists of Leigh Morgan, Pamela Esposito, Ph.D., and Gorjan Hrustanovic, Ph.D.